Formulation and bioequivalence of two valsartan tablets after a single oral administration

Scientia Pharmaceutica

Volumn 79, Issue 1, 2011, Pages 123-135

  Zaid, Abdel Naser ^a   Cortesi, Rita ^b   Qaddomi, Aiman ^c   Khammash, Saed ^a  

^a AN NAJAH NATIONAL UNIVERSITY   (Palestine)

^b UNIVERSITY OF FERRARA   (Italy)

^c Pharmacare Ltd Beitunia   (Palestine)

Author keywords

Bioequivalence; Diovan ; Formulation; HPLC; Immediate Release; Valsartan; Valzan

Indexed keywords

GENERIC DRUG; UNCLASSIFIED DRUG; VALSARTAN; VALZAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; VALIDATION STUDY;

EID: 79952972490     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.1009-01     Document Type: Article

References (25)

1. Diovan prescribing information: Novartis. http://www.pharma.us.novartis.com/product/pi/pdf/diovan.pdf.
2. Oparil S, Dyke S, Harris F, Kief J, James D, Hester A, Fitzsimmons S. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther. 1996; 18: 797-810. doi:10.1016/S0149-2918(96)80040-3
3. Black HR, Graff A, Shute D, Stoltz R, Ruff D, Levine J, Shi Y, Mallows S. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens. 1997; 11: 483-489. doi:10.1038/sj.jhh.1000482
4. Corea L, Cardoni O, Fogari R, Innocenti P, Porcellati C, Provvidenza M, Meilenbrock S, Sullivan J, Bodin F. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther. 1996; 60: 341-346. doi:10.1016/S0009-9236(96)90061-2
5. Holwerda NJ, Fogari R, Angeli P, Porcellati C, Hereng C, Oddou-Stock P, Heath R, Bodin F. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens. 1996; 14: 1147-1151. doi:10.1097/00004872-199609000-00016
6. Flesch G, Muller P, Lloyd P. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol. 1997; 52: 115-120. doi:10.1007/s002280050259
7. Muller P, Flesch G, de Gasparo M, Gasparini M, Howald H. Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects. Eur J Clin Pharmacol. 1997; 52: 441-449. doi:10.1007/s002280050317
8. Waldmeier F, Flesch G, Müller P, Winkler T, Kriemler HP, Bühlmayer P, De Gasparo M. Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica. 1997; 27: 59-71. doi:10.1080/004982597240767
9. Brookman LJ, Rolan PE, Benjamin IS, Palmer KR, Wyld PJ, Lloyd P, Flesch G, Waldmeier F, Sioufi A, Mullins F. Pharmacokinetics of valsartan in patients with liver disease. Clin Pharmacol Ther. 1997; 62: 272-8. doi:10.1016/S0009-9236(97)90029-1
10. Wang J, Ho L, Chen L, Zhao Z, Zhao W, Qian X, Humala N, Seror I, Bartholomew S, Rosendorff C, Pasinetti GM. Valsartan lowers brain?-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease: J Clin Invest. 2007; 117: 3393-3402. doi:10.1172/JCI31547
11. Daneshtalab N, Lewanczuk RZ, Jamali F. High-performance liquid chromatographic analysis of angiotensin II receptor antagonist valsartan using a liquid extraction method. J Chromatogr B Analyt Technol Biomed Life Sci. 2002; 766: 345-349. doi:10.1016/S0378-4347(01)00507-2
12. Macek J, Klima J, Ptacek P. Rapid determination of valsartan in human plasma by protein precipitation and high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2006; 832: 169-172. doi:10.1016/j.jchromb.2005.12.035
13. Sechaud R, Graf P, Bigler H, Gruendl E, Letzkus M, Merz M. Bioequivalence study of a valsartan tablet and a capsule formulation after single dosing in healthy volunteers using a replicated crossover design. Int J Clin Pharmacol Ther. 2002; 40: 35-40. PMid:11837381
14. Zakeri-Milani P, Valizadeh H, Islambulchilar Z, Nemati M. Pharmacokinetic and bioequivalence study of two brands of valsartan tablets in healthy male volunteers. Arzneimittelforschung. 2010; 60: 76-80. PMid:20329655
15. Zarghi A, Alireza S, Foroutan SM, Movahed H. Rapid Quantification of Valsartan in Human Plasma by Liquid Chromatography using a Monolithic Column and a Fluorescence Detection: Application for Pharmacokinetic Studies. Sci Pharm. 2008; 76: 439-450. doi:10.3797/scipharm.0808-01
16. Piao ZZ, Lee ES, Tran HT, Lee BJ. Improved analytical validation and pharmacokinetics of valsartan using HPLC with UV detection. Arch Pharm Res. 2008; 31: 1055-1059. doi:10.1007/s12272-001-1268-4
17. Tian DF, Tian XL, Tian T, Wang ZY, Mo FK. Simultaneous Determination of Valsartan and Hydrochlorothiazide in Tablets by RP-HPLC. Indian J Pharm Sci. 2008; 70: 372-374. doi:10.4103/0250-474X.43006
18. EMEA guidance. Note for guidance on the investigation of bioavailability and bioequivalence (CPMP/EWP/QWP/1401/98). London; 2001.
19. Chow S-C, Liu J-P. Design and analysis of bioavailability and bioequivalence studies. New York: M. Dekker; 1992.
20. FDA guidance. Guidance for industry: Statistical approaches to establishing bioequivalence. Rockville, MD; 2001.
21. Guideline for good clinical practice E6(R1): International conference on harmonisation (ICH) of technical requirements for registration of pharmaceuticals for human use; 1996.
22. Handbook: good laboratory practice (GLP): quality practices for regulated non-clinical research and development. 2nd ed: World Health Organization; 2009.
23. Pérez M, Cárdenas W, Ramírez G, Pérez M, Restrepo PV. Comparative, crossed, double blind, random study to determine the bioequivalence between two valsartan formulations in tablets and capsules. Colomb Med. 2006; 37: 107-113.
24. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Layloff T, Viswanathan CT, Cook CE, McDowall RD, Pittman KA, Spector S. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet. 1991; 16: 249-255. doi:10.1007/BF03189968
25. Viswanathan CT, Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad J, Shah VP, Skelly JP, Swann PG, Weiner R. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm Res. 2007; 24: 1962-1973. doi:10.1007/s11095-007-9291-7